@article{uoadl:3004197,
    volume = "118",
    number = "4",
    pages = "884-893",
    journal = "Blood advances",
    keywords = "deferasirox;  ferritin;  iron, abdominal pain;  adolescent;  adult;  article;  cardiopulmonary arrest;  child;  child growth;  cholelithiasis;  congestive heart failure;  controlled study;  creatinine blood level;  crossover procedure;  diarrhea;  dose response;  drug efficacy;  drug eruption;  drug exposure;  drug fever;  drug safety;  drug use;  drug withdrawal;  female;  ferritin blood level;  follow up;  glucosuria;  human;  hypersplenism;  hypertransaminasemia;  iron chelation;  iron overload;  liver biopsy;  liver level;  major clinical study;  male;  myocardial dysfunction;  nausea;  preschool child;  priority journal;  school child;  sexual development;  side effect;  thalassemia major;  vomiting",
    BIBTEX_ENTRY = "article",
    year = "2011",
    author = "Cappellini, M.D. and Bejaoui, M. and Agaoglu, L. and Canatan, D. and Capra, M. and Cohen, A. and Drelichman, G. and Economou, M. and Fattoum, S. and Kattamis, A. and Kilinc, Y. and Perrotta, S. and Piga, A. and Porter, J.B. and Griffel, L. and Dong, V. and Clark, J. and Aydinok, Y.",
    abstract = "Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66.8% completed the study; 43 patients (7.7%) discontinued because of adverse events. In patients with ≥ 4 years' deferasirox exposure who had liver biopsy, mean liver iron concentration significantly decreased by 7.8 ± 11.2 mg Fe/g dry weight (dw; n = 103; P < .001) and 3.1 ± 7.9 mg Fe/g dw (n = 68; P < .001) in the deferasirox and crossover cohorts, respectively. Median serum ferritin significantly decreased by 706 ng/mL (n = 196; P < .001) and 371 ng/mL (n = 147; P < .001), respectively, after ≥ 4 years'exposure. Investigator-assessed, drug-related adverse events, including increased blood creatinine (11.2%), abdominal pain (9.0%), and nausea (7.4%), were generally mild to moderate, transient, and reduced in frequency over time. No adverse effect was observed on pediatric growth or adolescent sexual development. This first prospective study of long-term deferasirox use in pediatric and adult patients with β- thalassemia suggests treatment for ≤ 5 years is generally well tolerated and effectively reduces iron burden. This trial was registered at www.clinicaltrials-.gov as #NCT00171210. © 2011 by The American Society of Hematology.",
    title = "Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up",
    doi = "10.1182/BLOOD-2010-11-316646"
}